Clinical trials: Sitagliptin
Cardiovascular Kidney Metabolic Syndrome
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Complex pathophysiological interactions among obesity, metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system lead to poor cardiovascular-kidney-metabolic health (CKMH), which is a major determinant…
- Trial name
- DASH-CKMH (NCT07188545)
- Testing
- Intervention, Active Comparator
- Where
- United States
- Volunteers
- 23,280,000 people
- Sponsor
- Ohio State University
Diabetes Mellitus, Type 2
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.
- Trial name
- NCT00716092
- Testing
- Sitagliptin, Linagliptin
- Where
- 3 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Objectives: To quantify differences in control of glycemia (primary objective) and the secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or placebo added to pre-existing therapy with…
- Trial name
- NCT01937598
- Testing
- Mixed meal test, Liraglutide, Sitagliptin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Michael A. Nauck
Type 2 Diabetes Mellitus
Sitagliptin Added-on to Insulin Study (0431-051)
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.
- Trial name
- NCT00395343
- Testing
- sitagliptin phosphate
- Volunteers
- 641 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Hyperglycemia
Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
This clinical trial investigates the effects of adding different diabetes medications to patients with type 2 diabetes who are currently being treated with DPP4 inhibitors.
- Conditions
- Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance
- Trial name
- NCT07108985
- Testing
- Sitagliptin 100 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
PDAC - Pancreatic Ductal Adenocarcinoma
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
The purpose of this study is to determine the efficacy of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.
- Trial name
- NCT05947825
- Testing
- Combination of sitagliptin+ gemcitabine + nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Reactive Hypoglycemia
Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism
The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.
- Trial name
- NCT00847080
- Testing
- Sitagliptin phosphate
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Liver Insufficiency
A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)
A study to compare the plasma concentrations of MK0431 at different times in patients with hepatic insufficiency vs healthy control subjects.
- Trial name
- NCT00696826
- Testing
- sitagliptin phosphate
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin.
- Trial name
- NCT01999218
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Glimerpiride
- Volunteers
- 1,326 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Events, Type2 Diabetes
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose…
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Trial name
- CER-4-T2D (NCT05220917)
- Testing
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA
- Where
- United States
- Volunteers
- 781,430 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus, Glucotoxicity
Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity
This study compares the efficacy and safety of sitagliptin phosphate combined with gliclazide sustained-release tablets versus metformin in treatment-naïve patients with type 2 diabetes mellitus (T2DM) and glucotoxicity.
- Trial name
- SG Metformin (NCT06613750)
- Testing
- Sitagliptin and Gliclazide, Metformin
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Zhibin Xu
Type 2 Diabetes
Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes
The study was an interventional non-randomized controlled study and was divided into a Sitagliptin monotherapy (100 mg Qd) group and a Sitagliptin (100mg Qd)+Beidougen capsule (60mg Tid) combination treatment group for one week.
- Trial name
- NCT05667220
- Testing
- Sitagliptin, Sitagliptin combined with Beidougen capsule
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Chao Yang Hospital
Type2 Diabetes
GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide
This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.
- Trial name
- NCT03845179
- Testing
- GIP receptor antagonist, DPP-4 inhibitor
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Covid19, Diabetes Mellitus, Type 2
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
The COVID-19 pathology is frequently associated with diabetes mellitus and metabolic syndrome. In the epidemic outbreak that exploded at the beginning of 2020 in the Lombardy Region, about two thirds of the patients who died from…
- Conditions
- Covid19, Diabetes Mellitus, Type 2, CKD
- Trial name
- SIDIACO (NCT04365517)
- Testing
- Sitagliptin
- Where
- Italy
- Volunteers
- 170 people
- Sponsor
- University of Milan
Type 2 Diabetes
Sitagliptin in Prevention of Type 2 Diabetes Mellitus
The hypothesis is, in subjects with persistent impaired glucose tolerance(IGT) , sitagliptin will decrease the conversion rate to diabetes as compared to a placebo in three years.
- Trial name
- SITAGLIPTIN (NCT01038648)
- Testing
- Sitagliptin, life style modification at base line
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
Graft Vs Host Disease
Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease
The prognosis of severe (grade 3-4) and steroid refractory acute graft-versus-host disease (GVHD) continues to be dismal. Sitagliptin given as GVHD-prophylaxis has recently been shown to reduce the incidence of acute GVHD to less…
- Trial name
- GVHD (NCT04448587)
- Testing
- Sitagliptin 100mg
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Diabetes Mellitus Type 1
Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes
Increasing evidence suggests pancreatic islet beta-cell regeneration occurs throughout the course of the disease in patients with type 1 diabetes.
- Trial name
- EXTYPE-1 (NCT02127047)
- Testing
- Sitagliptin, Exercise
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes Mellitus, Type 1
Sitagliptin Dose Determination Study
There are many recent advances in insulin treatment of type 1 diabetes, however after a meal sugars are always a concern. There is a drug sitagliptin (Januvia) which is FDA approved to treat people with type 2 diabetes which…
- Trial name
- NCT01530178
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Albert Einstein College of Medicine
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable insulin alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590797
- Testing
- Sitagliptin, Insulin, Metformin
- Volunteers
- 467 people
- Sponsor
- Merck Sharp & Dohme LLC